Disabled homolog 2 is required for migration and invasion of prostate cancer cells

doi:10.1007/s11684-015-0401-3

Frontiers of Medicine

2015, Vol. 9

Issue (3): 312-321 https://doi.org/10.1007/s11684-015-0401-3

本期目录

Disabled homolog 2 is required for migration and invasion of prostate cancer cells

Yinyin Xie¹,Yuanliang Zhang¹,Lu Jiang¹,Mengmeng Zhang¹,Zhiwei Chen¹,Dan Liu²,Qiuhua Huang^1,^*(

)

1. State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
2. Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China

全文: PDF(1815 KB) HTML

Abstract：

Disabled homolog 2 (DAB2) is frequently deleted or epigenetically silenced in many human cancer cells. Therefore, DAB2 has always been regarded as a tumor suppressor gene. However, the role of DAB2 in tumor progression and metastasis remains unclear. In this study, DAB2 expression was upregulated along with human prostate cancer (PCa) progression. DAB2 overexpression or knockdown effects in LNCaP and PC3 cell lines were verified to address the biological functions of DAB2 in PCa progression and metastasis. LNCaP and PC3 cell lines were generated from human PCa cells with low and high metastatic potentials, respectively. The results showed that DAB2 shRNA knockdown can inhibit the migratory and invasive abilities of PC3 cells, as well as the tumorigenicity, whereas DAB2 overexpression enhanced LNCaP cell migration and invasion. Further investigation showed that DAB2 regulated the cell migration associated genes in PC3 cells, and the differential DAB2 expression between LNCaP and PC3 cells was partly regulated by histone 4 acetylation. Therefore, DAB2 may play an important role in PCa progression and metastasis.

Key words： DAB2 prostate cancer migration invasion acetylation

收稿日期: 2015-03-20 出版日期: 2015-08-26

Corresponding Author(s): Qiuhua Huang

引用本文:

. [J]. Frontiers of Medicine, 2015, 9(3): 312-321.
Yinyin Xie,Yuanliang Zhang,Lu Jiang,Mengmeng Zhang,Zhiwei Chen,Dan Liu,Qiuhua Huang. Disabled homolog 2 is required for migration and invasion of prostate cancer cells. Front. Med., 2015, 9(3): 312-321.

链接本文:

https://academic.hep.com.cn/fmd/CN/10.1007/s11684-015-0401-3
https://academic.hep.com.cn/fmd/CN/Y2015/V9/I3/312

Fig.1

Fig.2

Fig.3

Fig.4

Fig.5

Fig.6

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69–90 https://doi.org/10.3322/caac.20107 pmid: 21296855
2	Jilg CA, Ketscher A, Metzger E, Hummel B, Willmann D, Rüsseler V, Drendel V, Imhof A, Jung M, Franz H, H?lz S, Kr?nig M, Müller JM, Schüle R. PRK1/PKN1 controls migration and metastasis of androgen-independent prostate cancer cells. Oncotarget 2014; 5(24): 12646–12664 pmid: 25504435
3	Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005; 280(43): 36529–36540 https://doi.org/10.1074/jbc.M503111200 pmid: 16127174
4	Xie S, Xie Y, Zhang Y, Huang Q. Effects of miR-145 on the migration and invasion of prostate cancer PC3 cells by targeting DAB2. Hereditas (Beijing) (Yi Chuan)2014; 36(1): 50–57 (in Chinese) https://doi.org/10.3724/SP.J.1005.2014.00050 pmid: 24846918
5	Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, Knapp RC, Berkowitz RS. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 1994; 52(2): 247–252 https://doi.org/10.1006/gyno.1994.1040 pmid: 8314147
6	Fu L, Rab A, Tang LP, Rowe SM, Bebok Z, Collawn JF. Dab2 is a key regulator of endocytosis and post-endocytic trafficking of the cystic fibrosis transmembrane conductance regulator. Biochem J 2012; 441(2): 633–643 https://doi.org/10.1042/BJ20111566 pmid: 21995445
7	Moore R, Cai KQ, Tao W, Smith ER, Xu XX. Differential requirement for Dab2 in the development of embryonic and extra-embryonic tissues. BMC Dev Biol 2013; 13(1): 39 https://doi.org/10.1186/1471-213X-13-39 pmid: 24168030
8	Jiang Y, Luo W, Howe PH. Dab2 stabilizes Axin and attenuates Wnt/β-catenin signaling by preventing protein phosphatase 1 (PP1)-Axin interactions. Oncogene 2009; 28(33): 2999–3007 https://doi.org/10.1038/onc.2009.157 pmid: 19581931
9	Chaudhury A, Hussey GS, Ray PS, Jin G, Fox PL, Howe PH. TGF-β-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol 2010; 12(3): 286–293 pmid: 20154680
10	Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139(5): 871–890 https://doi.org/10.1016/j.cell.2009.11.007 pmid: 19945376
11	Zhang Z, Chen Y, Tang J, Xie X. Frequent loss expression of dab2 and promotor hypermethylation in human cancers: a meta-analysis and systematic review. Pak J Med Sci 2014; 30(2): 432–437 pmid: 24772157
12	Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998; 16(18): 2381–2387 https://doi.org/10.1038/sj.onc.1201769 pmid: 9620555
13	Sheng Z, Sun W, Smith E, Cohen C, Sheng Z, Xu XX. Restoration of positioning cintrol following disabled-2 expression in ovarian and breast tumor cells. Oncogene 2000; 19(42): 4847–4854 pmid: 11039902
14	Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, Wang TH, Lai CH. Regulation of ovarian cancer progression by microRNA-187 through targeting disabled homolog-2. Oncogene 2012; 31(6): 764–775 https://doi.org/10.1038/onc.2011.269 pmid: 21725366
15	Teckchandani A, Toida N, Goodchild J, Henderson C, Watts J, Wollscheid B, Cooper JA. Quantitative proteomics identifies a Dab2/integrin module regulating cell migration. J Cell Biol 2009; 186(1): 99–111 https://doi.org/10.1083/jcb.200812160 pmid: 19581412
16	Chetrit D, Ziv N, Ehrlich M. Dab2 regulates clathrin assembly and cell spreading. Biochem J 2009; 418(3): 701–715 https://doi.org/10.1042/BJ20081288 pmid: 19000037
17	Orlandini M, Nucciotti S, Galvagni F, Bardelli M, Rocchigiani M, Petraglia F, Oliviero S. Morphogenesis of human endothelial cells is inhibited by DAB2 via Src. FEBS Lett 2008; 582(17): 2542– 2548 https://doi.org/10.1016/j.febslet.2008.06.025 pmid: 18582465
18	Zhang Y, Xie S, Zhou Y, Xie Y, Liu P, Sun M, Xiao H, Jin Y, Sun X, Chen Z, Huang Q, Chen S. H3K36 histone methyltransferase Setd2 is required for murine embryonic stem cell differentiation toward endoderm. Cell Reports 2014; 8(6): 1989–2002 https://doi.org/10.1016/j.celrep.2014.08.031 pmid: 25242323
19	Liu Y, Song N, Ren K, Meng S, Xie Y, Long Q, Chen X, Zhao X. Expression loss and revivification of RhoB gene in ovary carcinoma carcinogenesis and development. PLoS ONE 2013; 8(11): e78417 https://doi.org/10.1371/journal.pone.0078417 pmid: 24223801
20	Hanker LC, Karn T, Holtrich U, Graeser M, Becker S, Reinhard J, Ruckh?berle E, Gevensleben H, Rody A. Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer. Anticancer Res 2013; 33(2): 371–377 pmid: 23393326
21	Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T, Seki N. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol 2011; 38(4): 1093–1101 pmid: 21258769
22	Fu H, Wen JF, Hu ZL, Luo GQ, Ren HZ. Knockdown of fascin1 expression suppresses the proliferation and metastasis of gastric cancer cells. Pathology 2009; 41(7): 655–660 https://doi.org/10.3109/00313020903273100 pmid: 20001345
23	Murray MY, Birkland TP, Howe JD, Rowan AD, Fidock M, Parks WC, Gavrilovic J. Macrophage migration and invasion is regulated by MMP10 expression. PLoS ONE 2013; 8(5): e63555 https://doi.org/10.1371/journal.pone.0063555 pmid: 23691065
24	Xie XM, Zhang ZY, Yang LH, Yang DL, Tang N, Zhao HY, Xu HT, Li QC, Wang EH. Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers. Int J Oncol 2013; 43(5): 1636–1642 pmid: 24002585
25	Prunier C, Howe PH. Disabled-2 (Dab2) is required for transforming growth factor β-induced epithelial to mesenchymal transition (EMT). J Biol Chem 2005; 280(17): 17540–17548 https://doi.org/10.1074/jbc.M500974200 pmid: 15734730
26	Smith ER, Capo-chichi CD, He J, Smedberg JL, Yang DH, Prowse AH, Godwin AK, Hamilton TC, Xu XX. Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinonic acid in embryonic carcinoma cells. J Biol Chem 2001; 276(50): 47303–47310 https://doi.org/10.1074/jbc.M106158200 pmid: 11577091
27	Morris SM, Cooper JA. Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2. Traffic 2001; 2(2): 111–123 https://doi.org/10.1034/j.1600-0854.2001.020206.x pmid: 11247302
28	Xu XX, Yi T, Tang B, Lambeth JD. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene 1998; 16(12): 1561–1569 https://doi.org/10.1038/sj.onc.1201678 pmid: 9569023
29	Hocevar BA, Prunier C, Howe PH. Disabled-2 (Dab2) mediates transforming growth factor β (TGFβ)-stimulated fibronectin synthesis through TGFβ-activated kinase 1 and activation of the JNK pathway. J Biol Chem 2005; 280(27): 25920–25927 https://doi.org/10.1074/jbc.M501150200 pmid: 15894542
30	Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci 2004; 117( 20): 4619–4628 https://doi.org/10.1242/jcs.01481 pmid: 15371522
31	Hocevar BA, Smine A, Xu XX, Howe PH. The adaptor molecule disabled-2 links the transforming growth factor b receptors to the Smad pathway. EMBO J 2001; 20(11): 2789–2801 https://doi.org/10.1093/emboj/20.11.2789 pmid: 11387212

[1]

Download

Viewed

Full text

Abstract

Cited

Shared

Discussed